Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 5: 1059 - 1066

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.05.012

Original Articles

Jingui Shenqi pill (金匮肾气丸 ) treats cardiorenal syndrome by inhibiting mitogen-activated protein kinase signaling pathway and reducing inflammatory response

  • Shuyan HUANG ,
  • Xinyue DING ,
  • Hui ZHANG ,
  • Zongjun LIU ,
  • Yuling LUAN ,
  • Lina XING
Expand
  • Institute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China

Received date: 2024-09-02

  Accepted date: 2024-11-29

  Online published: 2025-09-15

Supported by

Shanghai Putuo District Health System Science and Technology Innovation Project: Study on the Effect and Mechanism of Jinkui Shenqi Pills on Renal Water Metabolism via provirus integration site for moloney murine leukemia virus 3/aquaporin 2 Regulation(PTKWS202104);Chengdu University of Traditional Chinese Medicine "Xinglin Scholar" Discipline Talent Research Enhancement Plan: Based on provirus integration site for moloney murine leukemia virus 3 to Explore the Molecular Mechanism of Jingui Shenqi pill in Regulating Water Metabolism in Renal Tubular Cells(YYZX2022165);Clinical Advantage Discipline of Health System of Putuo District in Shanghai(2019ysxk01)

Fold

Abstract

OBJECTIVE: To confirm the therapeutic effect and mechanism of Jingui Shenqi pill (金匮肾气丸, JGSQP) on cardiorenal syndrome.

METHODS: Doxorubicin was used to build heart-kidney coinjury rat model. After the modeling was completed, JGSQP gavage intervention was performed. The cardiac function of rats in each group was evaluated by ultrasound detection. Serum of rats was collected and examined for markers of heart and kidney damage. Enzyme linked immunosorbent assay detected serum inflammatory factors interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) expression. Quantitative real-time polymerase chain reaction (PCR) and Western blot detected the changes of related genes and proteins.

RESULTS: JGSQP significantly increased left ventricular ejection fraction (EF) and left ventricular shortening fraction (FS) values, decreased the heart and kidney damage markers and fibrosis levels (P < 0.05). Furthermore, it can reduce IL-1β, IL-6, and TNF-α inflammatory expression (P < 0.05). Mechanistically, JGSQP significantly inhibited the expression of key genes and proteins of mitogen-activated protein kinase (MAPK) signaling pathway (P < 0.05).

CONCLUSIONS: Jingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.

Key words： cardiorenal syndrome; mitogen-activated protein kinase; inflammatory cytokines; signal transduction; Jingui Shenqi pill

Cite this article

Shuyan HUANG , Xinyue DING , Hui ZHANG , Zongjun LIU , Yuling LUAN , Lina XING . Jingui Shenqi pill (金匮肾气丸 ) treats cardiorenal syndrome by inhibiting mitogen-activated protein kinase signaling pathway and reducing inflammatory response[J]. Journal of Traditional Chinese Medicine, 2025 , 45(5) : 1059 -1066 . DOI: 10.19852/j.cnki.jtcm.2025.05.012

References

1. Ricci Z, Romagnoli S, Ronco C. Cardiorenal syndrome. Crit Care Clin 2021; 37: 335-47.
2. Alprecht-Quiroz P, Zú?iga-Pineda B, Lara-Terán JJ, Cáceres-Vinueza SV, Duarte-Vera YC. Cardiorenal syndrome: clinical and echocardiographic aspects. Arch Cardiol Mex 2020; 90: 503-10.
3. Orvalho JS, Cowgill LD. Cardiorenal syndrome: diagnosis and management. Vet Clin N Am-small 2017; 47: 1083-102.
4. Chávez-I?iguez JS, Sánchez-Villaseca SJ, García-Macías LA. Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review. Arch Cardiol Mex 2022; 92: 253-63.
5. Junho CVC, Trentin-Sonoda M, Panico K, et al. Cardiorenal syndrome: long road between kidney and heart. Heart Fall Rev 2022; 27: 2137-53.
6. Brandenburg V, Heine GH. The cardiorenal syndrome. Deut Med Wochenschr 2019; 144: 382-6.
7. Lyu TJ, FA JJ, Xing LN. Research progress of Jinkui Shenqi pill in treatment of chronic kidney disease. Shi Jie Zhong Xi Yi Jie He Za Zhi 2019; 19: 1270-2.
8. Liang XW, Lai H, Wu J, et al. Effect of Jinkui shenqi pills on the level of monoamine neurotransmitters in kidney-Yang deficiency rats. Zhong Guo Zhong Yi Ji Chu Yi Xue Za Zhi 2024; 30: 1-15.
9. Kao ST, Wang SD, Lin CC, Lin LJ. Jin Gui Shen Qi Wan. A Traditional Chinese Medicine, alleviated allergic airway hypersensitivity and inflammatory cell infiltration in a chronic asthma mouse model. J Ethnopharmacol 2018; 227: 181-90.
10. Xiong X, Wang P, Li X, Zhang Y. Shenqi pill, a traditional Chinese herbal formula, for the treatment of hypertension: a systematic review. Complement Ther Med 2015; 23: 484-93.
11. Liang D, Qi Y, Liu L, et al. Jin-gui-shen-qi Wan ameliorates diabetic retinopathy by inhibiting apoptosis of retinal ganglion cells through the Akt/HIF-1α pathway. Chin Med-UK 2023; 18: 130.
12. Patel KP, Katsurada K, Zheng H. Cardiorenal syndrome: the role of neural connections between the heart and the kidneys. Circ Res 2022; 130: 1601-17.
13. Kosiorek A, Biegus J, Rozentryt P, Hurkacz M, Zymliński R. Cardiorenal syndrome: decongestion in heart failure across wide spectrum of kidney pathophysiology. Adv Clin Exp Med 2022; 31: 445-55.
14. Langlo KAR, Lundgren KM, Zanaboni P, et al. Cardiorenal syndrome and the association with fitness: data from a telerehabilitation randomized clinical trial. ESC Heart Fail 2022; 9: 2215-24.
15. McCallum W, Sarnak MJ. Cardiorenal syndrome in the hospital. Clin Jam Soc Nephro: CJASN 2023; 18: 933-45.
16. Jefferies JL, Kovesdy CP, Ronco C. Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis - a call for action. AM Heart J 2023; 261: 75-84.
17. Mei SB, Hong L, Cai XY, Xiao B, Zhang P, Shao L. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett 2019; 307: 41-8.
18. Wang L, Hao D, Li X, et al. Advances in animal models of cardiorenal syndrome. Zhong Guo Yao Li Xue Tong Bao 2013; 29: 1496-8.
19. Oremek GM, Passek K, Holzgreve F, von der Eltz V, Dr?ge J. The biomarkers BNP and NT-proBNP. Zhi Ye Yi Xue Zhi Ye An Quan Yu Ren Ti Gong Cheng Xue Zhong Yang Za Zhi 2023; 73: 89-5.
20. Nougué H, Michel T, Picard F, et al. Deconvolution of BNP and NT-proBNP immunoreactivities by mass spectrometry in heart failure and sacubitril/valsartan treatment. Clin Chem 2023; 69: 350-62.
21. Myhre PL, Vaduganathan M, Claggett BL, et al. Influence of NT-proBNP on efficacy of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC Heart failure 2022; 10: 902-13.
22. Xie C, Zhan Y, Wu Y, et al. Expression and clinical significance of serum sST2, BDNF, CTnI, and BUN/Cr in patients with heart failure. Altern Ther Health M 2023; 29: 176-81.
23. Miao Y, Liu Y, Liu C, Yao L, Kang X, Lyu M. Diagnostic value of echocardiography combined with serum h-FABP and cTnI in myocardial infarction and its evaluation value in left ventricular function. Evid-based Compl Alt: eCAM 2022; 2022: 8809708.
24. Lu P, Lin D, Chen N, et al. CNN-assisted SERS enables ultra-sensitive and simultaneous detection of Scr and BUN for rapid kidney function assessment. Anal Methods 2023; 15: 322-32.
25. Xu X, Ye B, Li M, Xia Y, Wu Y, Cheng W. The UA doppler index, plasma HCY, and Cys C in pregnancies complicated by congenital heart disease of the fetus. J Clin Med 2022; 11: 59-62.
26. Huang W, Wang L, Wan X. Monocyte to high density lipoprotein ratio in patients with acute kidney injury after cardiac surgery. Perfusion 2023; 38: 172-7.
27. Chung EYM, Trinh K, Li J, et al. Biomarkers in cardiorenal syndrome and potential insights into novel therapeutics. Front Cardiovasc Med 2022; 9: 868658.
28. Chen W, Fan Z, Huang C, Liu J. Poricoic acid A inhibits the NF-κB/MAPK pathway to alleviate renal fibrosis in rats with cardiorenal syndrome. Evid-based Compl Alt: eCAM 2022; 2022: 8644353.
29. Alasmari WA, Faruk E, Fouad H, Radi R, El-Wafaey DI. Adipose-derived stem cell and their extracellular vesicles ameliorates immune function, and cardiac markers in experimental model of cardiorenal syndrome type Ⅲ: TNF-α, IFN-γ and IL-10 cytokine production and their correlation with genotype. Transpl immunol 2022; 72: 101586.
30. Ma L, Wu F, Shao Q, et al. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway. Drug Des Dev Ther 2021; 15: 3207-21.
Options
Outlines

/

〈 〉